BLASUBCUTANEOUSSOLUTION
Approved
Feb 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Drug data last refreshed 26m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Toujeo SoloStar is a long-acting basal insulin analog (insulin glargine) administered as a subcutaneous injection for type 1 and type 2 diabetes management. It provides steady, 24-hour glucose control and is a cornerstone therapy in insulin-dependent diabetes regimens. The drug works by mimicking the body's natural basal insulin secretion.
$542MPart D
PeakPeak-cycle product with substantial Medicare claims volume signals stable commercial infrastructure and mature team operations.
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Started Aug 2025
877 enrolled
Diabetes Mellitus, Type 1
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
Started Apr 2024
429 enrolled
Diabetes, Type 2
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
Started Feb 2024
485 enrolled
Type 2 Diabetes
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Started Nov 2023
546 enrolled
Type 2 Diabetes
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Started Apr 2023
2,749 enrolled
Type 2 DiabetesObesityOverweight or Obesity+3 more
Worked on TOUJEO SOLOSTAR at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.